O13: Oral infigratinib for children with achondroplasia: Month 18 results from the PROPEL 2 study
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Genetics in Medicine Open |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949774425001281 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849711845224480768 |
|---|---|
| author | Ravi Savarirayan Elena Muslimova Josep Bergua Paul Arundel Jean Salles Vrinda Saraff Borja Delgado Antonio Leiva-Gea Helen McDevitt Marc Nicolino Massimiliano Rossi Maria Salcedo Valerie Cormier-Daire Mars Skael Peter Kannu John Phillips Howard Saal Paul Harmatz Toby Candler Richard Weng Yun Bai Supriya Raj Julie Hoover-Fong Melita Irving Daniela Rogoff |
| author_facet | Ravi Savarirayan Elena Muslimova Josep Bergua Paul Arundel Jean Salles Vrinda Saraff Borja Delgado Antonio Leiva-Gea Helen McDevitt Marc Nicolino Massimiliano Rossi Maria Salcedo Valerie Cormier-Daire Mars Skael Peter Kannu John Phillips Howard Saal Paul Harmatz Toby Candler Richard Weng Yun Bai Supriya Raj Julie Hoover-Fong Melita Irving Daniela Rogoff |
| author_sort | Ravi Savarirayan |
| collection | DOAJ |
| format | Article |
| id | doaj-art-b4f5cc626b4a4c478f664f88a1a2d595 |
| institution | DOAJ |
| issn | 2949-7744 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Genetics in Medicine Open |
| spelling | doaj-art-b4f5cc626b4a4c478f664f88a1a2d5952025-08-20T03:14:31ZengElsevierGenetics in Medicine Open2949-77442025-01-01310208910.1016/j.gimo.2025.102089O13: Oral infigratinib for children with achondroplasia: Month 18 results from the PROPEL 2 studyRavi Savarirayan0Elena Muslimova1Josep Bergua2Paul Arundel3Jean Salles4Vrinda Saraff5Borja Delgado6Antonio Leiva-Gea7Helen McDevitt8Marc Nicolino9Massimiliano Rossi10Maria Salcedo11Valerie Cormier-Daire12Mars Skael13Peter Kannu14John Phillips15Howard Saal16Paul Harmatz17Toby Candler18Richard Weng19Yun Bai20Supriya Raj21Julie Hoover-Fong22Melita Irving23Daniela Rogoff24Murdoch Children’s Research Institute, Melbourne, AustraliaBridgeBio Pharma, San Francisco, CAHospital Vithas San José, Vitoria-Gasteiz, SpainSheffield Children’s NHS Foundation Trust, Sheffield, UKHôpital des Enfants – Toulouse, Toulouse, FranceBirmingham Women’s and Children’s NHS Foundation Trust, Birmingham, UKHospital Universitario Virgen de la Victoria, Malaga, SpainHospital Universitario Virgen de la Victoria, Malaga, SpainNHS Greater Glasgow and Clyde, Glasgow, UKHôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, FranceHôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, FranceHospital Universitario La Paz, Madrid, SpainHôpital Necker-Enfants Malades, Paris, FranceManchester University NHS Foundation Trust, Manchester, UKUniversity of Alberta – Stollery Children’s Hospital, Edmonton, CanadaVanderbilt University Medical Center, Nashville, TN15Cincinnati Children’s Hospital Medical Center, Cincinnati, OHBenioff Children’s Hospital Oakland, Oakland, CAUniversity Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UKBridgeBio Pharma, San Francisco, CABridgeBio Pharma, San Francisco, CAMurdoch Children’s Research Institute, Melbourne, AustraliaJohns Hopkins, Department of PediatricsGuy’s and St Thomas’ NHS Foundation Trust, London, UKBridgeBio Pharma, San Francisco, CAhttp://www.sciencedirect.com/science/article/pii/S2949774425001281 |
| spellingShingle | Ravi Savarirayan Elena Muslimova Josep Bergua Paul Arundel Jean Salles Vrinda Saraff Borja Delgado Antonio Leiva-Gea Helen McDevitt Marc Nicolino Massimiliano Rossi Maria Salcedo Valerie Cormier-Daire Mars Skael Peter Kannu John Phillips Howard Saal Paul Harmatz Toby Candler Richard Weng Yun Bai Supriya Raj Julie Hoover-Fong Melita Irving Daniela Rogoff O13: Oral infigratinib for children with achondroplasia: Month 18 results from the PROPEL 2 study Genetics in Medicine Open |
| title | O13: Oral infigratinib for children with achondroplasia: Month 18 results from the PROPEL 2 study |
| title_full | O13: Oral infigratinib for children with achondroplasia: Month 18 results from the PROPEL 2 study |
| title_fullStr | O13: Oral infigratinib for children with achondroplasia: Month 18 results from the PROPEL 2 study |
| title_full_unstemmed | O13: Oral infigratinib for children with achondroplasia: Month 18 results from the PROPEL 2 study |
| title_short | O13: Oral infigratinib for children with achondroplasia: Month 18 results from the PROPEL 2 study |
| title_sort | o13 oral infigratinib for children with achondroplasia month 18 results from the propel 2 study |
| url | http://www.sciencedirect.com/science/article/pii/S2949774425001281 |
| work_keys_str_mv | AT ravisavarirayan o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT elenamuslimova o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT josepbergua o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT paularundel o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT jeansalles o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT vrindasaraff o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT borjadelgado o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT antonioleivagea o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT helenmcdevitt o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT marcnicolino o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT massimilianorossi o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT mariasalcedo o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT valeriecormierdaire o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT marsskael o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT peterkannu o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT johnphillips o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT howardsaal o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT paulharmatz o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT tobycandler o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT richardweng o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT yunbai o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT supriyaraj o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT juliehooverfong o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT melitairving o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study AT danielarogoff o13oralinfigratinibforchildrenwithachondroplasiamonth18resultsfromthepropel2study |